🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

An International Challenge

Gonorrhoea infections are escalating globally, with figures suggesting over 82 million infections per year. Notably increased rates are seen in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs at this time.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program found that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Experts believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, was also approved in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to develop it.

“This authorization represents a significant shift in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Research Study Data and Worldwide Availability

As per findings released by a prominent scientific publication, the new drug successfully treated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The trial included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the authority to register and commercialise the drug in numerous developing nations.

Medical professionals directly involved have shared hope. Access to a one-pill regimen such as this is seen as a "game-changer" for managing the epidemic. This is deemed vital to lessen the impact of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.